Everolimus Approved for GI, Lung Neuroendocrine Tumors


Everolimus (Afinitor) treats progressive, non-functional neuroendocrine tumors of gastrointestinal or lung origin.

A new treatment was approved today by the FDA for the treatment of progressive, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.

The approval of everolimus (Afinitor) followed a randomized (2:1) clinical trial with 302 patients that suffered from NET of GI or lung origin and showed evidence of disease progression within 6 months prior to randomization.

Patients in the trial were administered either 10 mg of Afinitor orally and daily with best supportive care (BSC) or a placebo and BSC.

Progression-free survival (PFS) was the major efficacy outcome measure based on independent radiological assessment per RECIST.

The results of the study showed patients administered Afinitor plus BSC had a median PFS of 11 months, while the placebo group plus BSC was 3.9 months [HR 0.48 (95% CI: 0.35, 0.67), p <0.001, stratified log rank test].

The overall response rate in the Afinitor group was 2% compared to with 1% in the placebo group.

When researchers reached the planned interim analysis, they found that there was not a statistically significant difference in overall survival rate between the 2 groups.

When the safety data was evaluated for 300 participants who received at least 1 dose of Afinitor, it showed a median exposure duration of 9.3 months. About 64% of patients were treated for greater than or equal to 6 months, and 39% were treated for 12 months.

Adverse reactions in 29% of patients led to a discontinuation, dose reduction, or delay of Afinitor. Three fatal adverse events occurred: cardiac failure, respiratory failure, and septic shock, which effected 42% of participants.

The most common adverse reactions were stomatitis, diarrhea, peripheral edema, infection, fatigue, and rash.

The common laboratory abnormalities were elevated aspartate transaminase (AST), fasting hyperglycemia, anemia, hypercholesterolemia, and lymphopenia.

Related Videos
Image Credit: © Anastasiia - stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
Image Credit: © Dragana Gordic - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
car t cell therapy multiple myeloma/Image Credit: © Lusi_mila - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.